Fig. 7.

Lysis by Vγ9Vδ2 T cells of zoledronate-pretreated tumor cells. Target cells were pretreated overnight with 5 μM zoledronate. Viability of the cells was unchanged after this pretreatment. Then, 5 × 10³ target cells were labeled with ⁵¹Cr and incubated for 4 h with Vγ9Vδ2 T cells in a ratio effector to target (E/T) of 50/1. a Target cells were from HCC (HepG2, n = 8; HuH7, n = 8) and CRC (C181, n = 10; C187, n = 8; HT29, n = 6; SW620, n = 6). Effector cells were Vγ9Vδ2 T cells expanded from two donors and one CRC patient. *, P ≤ 0.04 compared with untreated target cells. b Target cells were normal hepatic cells and tumor cells isolated from a liver metastasis from the patient C335. Effector cells were autologous (C335) or allogeneic (H334) Vγ9Vδ2 T cells expanded from patients C335 and H334